Experienced in Relapsing Polychondritis

Francois Lebargy

Reims, FR 
Experienced in Relapsing Polychondritis
Reims, FR 
OverviewLocationsClinical Research

Overview

Francois Lebargy practices in Reims, France. Mr. Lebargy is rated as an Experienced expert by MediFind in the treatment of Relapsing Polychondritis. His top areas of expertise are Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Acute Interstitial Pneumonia, Lung Transplant, and Splenectomy.

His clinical research consists of co-authoring 71 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Relapsing Polychondritis.

Gender
Male

Locations

Reims, France
Other Locations
Besancon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: August 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
View 1 Less Clinical Trial

71 Total Publications

Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review.
Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review.
Journal: The Journal of antimicrobial chemotherapy
Published: November 07, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lebargy's expertise for a condition
ConditionClose
      View All 31 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile